Details of the Drug

General Information of Drug (ID: DMA5DDI)

Drug Name

NGM707

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Antibody

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukocyte immunoglobulin-like receptor B2 (LILRB2)	TTHC6XU	LIRB2_HUMAN	Antagonist	[2]
Leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1)	TTC0QRJ	LIRB1_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04913337) A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of NGM Biopharma